Eric K. Singhi: Emerging TKIs in the HER2 space at ASCO
Eric K. Singhi shared the following on X:
”Beamion LUNG-1: Zongertinib in patients with HER2 aberration + (ph 1a) and HER2 mutation + mNSCLC (ph 1b).
Ph 1a
- 36 patients with NSCLC,
- ORR 58%; DCR 97%.
Ph 1b
- 23 patients,
- ORR 74%; DCR 91%,
- AEs: diarrhea, rash.
Emerging TKIs in the HER2 space.”
Source: Eric K. Singhi/X
Dr. Eric K. Singhi is a thoracic and head and neck medical oncologist, currently serving as an Assistant Professor in the Department of General Oncology within the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston, TX.
Dr. Singhi is highly skilled in general internal medicine and hematology/oncology, with a special focus on thoracic medical oncology. Fluent in multiple languages, including Hindi and Spanish, he is dedicated to providing personalized care and improving patient outcomes. Dr. Singhi’s interests extend to patient education, patient-reported outcomes, and community outreach.
He is affiliated with various hospitals in the Houston area, including Harris Health Ben Taub General and LBJ Hospitals, and The University of Texas MD Anderson Cancer Center. With over 6-10 years of experience, Dr. Eric K. Singhi is committed to delivering exceptional care to his patients and advancing the field of oncology.